GeneBiology, Inc. is dedicated to improving human health through innovation, and combines its expertise in medicine, drug development and formulation chemistry to identify, develop, and market patented new formulations/new routes of administration/new indications for approved medicines under the 505(b)(2) regulatory pathway. The 505(b)(2) pathway is the fastest, least expensive, and lowest risk regulatory pathway for development of important new drugs, because both data on file for prior approval(s) and published data can be used to fulfill regulatory requirements for both clinical development and commercial approval, thereby substantially reducing the costs (in time and money) and the risks of developing new drugs.